EP1307477A2 - Nucleotide sequences which code for the metf gene - Google Patents

Nucleotide sequences which code for the metf gene

Info

Publication number
EP1307477A2
EP1307477A2 EP01967192A EP01967192A EP1307477A2 EP 1307477 A2 EP1307477 A2 EP 1307477A2 EP 01967192 A EP01967192 A EP 01967192A EP 01967192 A EP01967192 A EP 01967192A EP 1307477 A2 EP1307477 A2 EP 1307477A2
Authority
EP
European Patent Office
Prior art keywords
gene
codes
polynucleotide
methionine
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01967192A
Other languages
German (de)
French (fr)
Inventor
Brigitte Bathe
Bettina Möckel
Walter Pfefferle
Klaus Huthmacher
Michael Binder
Dieter Greissinger
Georg Thierbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10109686A external-priority patent/DE10109686A1/en
Application filed by Degussa GmbH filed Critical Degussa GmbH
Publication of EP1307477A2 publication Critical patent/EP1307477A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • C12P13/12Methionine; Cysteine; Cystine

Definitions

  • the invention provides nucleotide sequences from coryneform bacteria which code for the etF gene and a process for the fermentative preparation of amino acids, in particular L- methionine, using bacteria in which the metF gene is enhanced.
  • L-Amino acids in particular L-methionine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.
  • amino acids are prepared by fermentation from strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
  • fermentation measures such as, for example, stirring and supply of oxygen
  • the composition of the nutrient media such as, for example, the sugar concentration during the fermentation
  • the working up to the product form by, for example, ion exchange chromatography or the intrinsic output properties of the microorganism itself.
  • Strains which are resistant to antimetabolites such as e.g. the methionine analogue ⁇ - methyl-methionine, ethionine, norleucine, N- acetylnorleucine, S-trifluoromethylhomocysteine, 2-amino-5- heprenoitic acid, seleno-methionine, ethionine- sulfoximine, methoxine, 1-aminocyclopentane-carboxylic acid, or are auxotrophic for metabolites of regulatory importance and produce amino acid, such as e.g. - methionine, are obtained in this manner.
  • antimetabolites such as e.g. the methionine analogue ⁇ - methyl-methionine, ethionine, norleucine, N- acetylnorleucine, S-trifluoromethylhomocysteine, 2-amino-5- heprenoitic acid, sel
  • the inventors had the object of providing new measures for • improved fermentative preparation of amino acids, in particular L-methionine.
  • the invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the metF gene, chosen from the group consisting of
  • polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID.No. 2,
  • polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,
  • polynucleotide which is complementary to the polynucleotides of a) or b) , and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c),
  • polypeptide preferably having the activity of methylene tetrahydrofolate reductase.
  • the invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:
  • the invention also provides
  • a vector containing the polynucleotide according to the invention in particular a shuttle vector or plasmid vector, and
  • the invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library, which comprises the complete gene with the polynucleotide sequence corresponding to SEQ ID No. 1, with a probe which comprises the sequence of the polynucleotide mentioned, according to SEQ ID No. 1 or a fragment thereof, and isolation of the DNA sequence mentioned.
  • Polynucleotides which comprise the sequences according to the invention are suitable as hybridization probes for RNA, cDNA and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for methylene tetrahydrofolate reductase or to isolate those nucleic acids or polynucleotides or genes which have a high similarity of sequence to methylene tetrahydrofolate reductase.
  • Polynucleotides which comprise the sequences according to the invention are furthermore suitable as primers with the aid of which DNA of genes which code for methylene tetrahydrofolate reductase can be prepared by the polymerase chain reaction (PCR) .
  • PCR polymerase chain reaction
  • Such oligonucleotides which serve as probes or primers comprise at least 30, preferably at least 20, very particularly preferably at least 15 successive nucleotides. Oligonucleotides which have a length of at least 40 or 50 nucleotides are also suitable. Oligonucleotides with a length of at least 100, 150, 200, 250 or 300 nucleotides are optionally also suitable.
  • Polynucleotide in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA or DNA or modified RNA or DNA.
  • Polypeptides are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.
  • polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of methylene tetrahydrofolate reductase, and also those which are at least 70%, preferably at least 80% and in particular which are at least 90% to 95% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.
  • the invention moreover provides a process for- the fermentative preparation of amino acids, in particular L- methionine, using coryneform bacteria which in particular already produce amino acids, and in which the nucleotide sequences which code for the metF gene are enhanced, in particular over-expressed.
  • enhancement in this connection describes the increase in the intracellular activity of one or more enzymes in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or using a gene which codes for a corresponding enzyme having a high activity, and optionally combining these measures.
  • the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on the starting microorganism.
  • the microorganisms which the present invention provides can prepare L-amino acids, in particular L-methionine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of coryneform bacteria, in particular of the genus Corynebacterium. Of the genus Corynebacterium, there may be mentioned in particular the species
  • Suitable strains of the genus Corynebacterium in particular of the species Corynebacterium glutamicum (C. glutamicum) , are in particular the known wild-type strains
  • L-amino acid-producing mutants or strains prepared therefrom such as, for example, the L-methionine-producing strain
  • E. coli Escherichia coli
  • the setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: Gene und Klone, Amsterdam Einf ⁇ hrung in die Gentechnologie (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example.
  • a well-known gene library is that of- the E. coli K-12 strain W3110 set up in ⁇ vectors by Kohara et al. (Cell 50, 495 -508 (1987)).
  • plasmids such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268).
  • Suitable hosts are, in particular, those E. coli strains which are restriction- and recombination- defective.
  • An example of these is the strain DH5 ⁇ mcr, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649).
  • the long DNA fragments cloned with the aid of cos ids can in turn be subcloned in the usual vectors suitable for sequencing and then sequenced, as is described e.g. by Sanger et al. (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977) .
  • the resulting DNA sequences can then be investigated with known algorithms or sequence analysis programs, such as e.g. that of Staden (Nucleic Acids Research 14, 217- 232(1986)), that of Marck (Nucleic Acids Research 16, 1829- 1836 (1988)) or the GCG program of Butler (Methods of Biochemical Analysis 39, 74-97 (1998)).
  • the new DNA sequence of C. glutamicum which codes for the metF gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found.
  • the amino acid sequence of the corresponding protein has furthermore been derived from the present DNA sequence by the methods described above.
  • the resulting amino acid sequence of the metF gene product is shown in SEQ ID No. 2.
  • Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention.
  • DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention.
  • Conservative amino acid exchanges such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function.
  • DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention.
  • DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention.
  • PCR polymerase chain reaction
  • Such oligonucleotides typically have a length of at least 15 nucleotides.
  • PCR polymerase chain reaction
  • coryneform bacteria produce amino acids, in particular L-methionine, in an improved manner after over-expression of the metF gene.
  • the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated.
  • Expression cassettes which are incorporated upstream of the structural gene act in the same way.
  • inducible promoters it is additionally possible to increase the expression in the course of fermentative L-methionine production.
  • the expression is likewise improved by measures to prolong the life of the m-RNA.
  • the enzyme activity is also increased by preventing the degradation of the enzyme protein.
  • the genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an over- expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.
  • Suitable plasmids are those which are • replicated in coryneform bacteria.
  • Numerous known plasmid vectors such as e.g. pZl (Menkel et al., Applied and Environmental Microbiology (1989) 64: 549-554), pEKExl (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-l (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBLl or pGAl .
  • plasmid vectors such as e.g. those based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al., FEMS Microbiology Letters 66, 119- 124 (1990)), or pAGl (US-A 5,158,891), can be used in the same manner.
  • Plasmid vectors which are furthermore suitable are also those with the aid of which the process of gene amplification by integration into the chromosome can be used, as has been described, for example, by Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)) for duplication or amplification of the hom-thrB operon.
  • the complete gene is cloned in a plasmid vector which can replicate in a host (typically E. coli) , but not in C. glutamicum.
  • Possible vectors are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pKl ⁇ mob or pK19mob (Schafer et al., Gene 145, 69- 73 (1994)), pGEM-T (Promega corporation, Madison, WI, USA), PCR2.1-TOPO (Shuman (1994). Journal of Biological Chemistry 269:32678-84; US-A 5, 487, 993) , ⁇ CR®Blunt (Invitrogen,
  • the plasmid vector which contains the gene to be amplified is then transferred into the desired strain of C. glutamicum by conjugation or transformation.
  • the method of conjugation is described, for example, by Schafer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods for transformation are described, for example, by Thierbach et al.
  • amino acids in particular L-methionine
  • amino acids in particular L- methionine
  • amino acids in particular L-methionine
  • metF gene for one or more genes chosen from the group consisting of
  • the term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter ' or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein) , and optionally combining these measures.
  • the activity or concentration of the corresponding protein is in general reduced to 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein.
  • metF gene it may furthermore be advantageous, for the production of amino acids, in particular L-methionine, to eliminate undesirable side reactions, (Nakayama: “Breeding of Amino Acid Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982) .
  • amino acids in particular L-methionine
  • microorganisms prepared according to the invention can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of amino acids, in particular L- methionine.
  • batch culture batch culture
  • feed process fed batch
  • repetitive feed process repetition feed process
  • a summary of known culture methods is described in the textbook by Chmiel (Bioreatechnik 1. Einfiihrung in die Biovonstechnik (Gustav Fischer Verlag, Stuttgart, 1991) ) or in the textbook by Storhas (Bioreaktoren und periphere bamboo (Vieweg Verlag, Braunschweig/Wiesbaden, 1994) ) .
  • the culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook “Manual of Methods for General Bacteriology” of the American Society for Bacteriology (Washington D.C., USA, 1981).
  • Sugars and carbohydrates such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substance can be used individually or as a mixture.
  • oils and fats such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat
  • fatty acids such as e.g. palmitic acid, stearic acid and linoleic acid
  • alcohols such as e.g. glycerol and ethanol
  • organic acids such as e.g. acetic acid
  • Organic nitrogen-containing compounds such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea
  • inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen.
  • the sources of nitrogen can be used individually or as a mixture.
  • Organic and inorganic sulfur-containing compounds such as, for example, sulfides, sulfites, sulfates and thiosulfates, can be used as a source of sulfur, in particular for the preparation of methionine.
  • Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium- containing salts can be used as the source of phosphorus.
  • the culture medium must furthermore comprise salts of metals, such as e. g. magnesium sulfate or iron sulfate, which are necessary for growth.
  • essential growth substances such as amino acids and vitamins, can be employed in addition to the above-mentioned substances.
  • Suitable precursors can moreover be added to the culture medium.
  • the starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.
  • Basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture.
  • Antifoams such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam.
  • Suitable substances having a selective action such as e.g. antibiotics, can be added to the medium to maintain the stability of plasmids.
  • oxygen or oxygen-containing gas mixtures such as e.g. air, are introduced into the culture.
  • the temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the. desired product has formed. This target is usually reached within 10 hours to 160 hours.
  • the fermentation broths obtained in this way in particular containing L-methionine, usually have a dry weight of 7.5 to 25 wt.% and contain L-methionine. It is furthermore also advantageous if the fermentation is conducted in a sugar- limited procedure at least at the end, but in particular over at least 30% of the duration of the fermentation. That is to say, the concentration of utilizable sugar in the fermentation medium is reduced to ⁇ 0 to 3 g/1 during this period.
  • the fermentation broth prepared in this manner is then further processed.
  • all or some of the biomass can be removed from the fermentation broth by separation methods, such as e.g. centrifugation, filtration, decanting or a combination thereof, or it can be left completely in this.
  • This broth is then thickened or concentrated by known methods, such as e.g. with the aid of a rotary evaporator, thin film evaporator, falling film evaporator, by reverse osmosis, or by nanofiltration.
  • This concentrated fermentation broth can then be worked up by methods of freeze drying, spray drying, spray granulation or by other processes to give a preferably free-flowing, finely divided powder.
  • This free-flowing, finely divided powder can then in turn by converted by suitable compacting or granulating processes into a coarse-grained, readily free-flowing, storable and largely dust-free product.
  • suitable compacting or granulating processes into a coarse-grained, readily free-flowing, storable and largely dust-free product.
  • organic or inorganic auxiliary substances or carriers such as starch, gelatin, cellulose derivatives or similar substances, such as are conventionally used as binders, gelling agents or thickeners in foodstuffs or feedstuffs processing, or further substances, such as, for example, silicas, silicates or stearates.
  • Free-flowing is understood as meaning powders which flow unimpeded out of the vessel with the opening of 5 mm (millimeters) of a series of glass outflow vessels with outflow openings of various sizes (Klein, Seifen, Ole, Fette, Wachse 94, 12 (1968)).
  • finely divided means a powder with a predominant content (> 50 %) with a particle size of 20 to
  • the product described above is suitable as a feedstuffs additive, i.e. feed additive, for animal nutrition.
  • the L-methionine content of the animal feedstuffs additive is conventionally 1 wt.% to 80 wt.%, preferably 2 wt.% to 80 wt.%, particularly preferably 4 wt.% to 80 wt.%, and very particularly preferably 8 wt.% to.80 wt.%, based on the dry weight of the animal feedstuffs additive. Contents of 1 wt.% to 60 wt.%, 2 wt.% to 60 wt .
  • the water content of the feedstuffs additive is conventionally up to 5 wt.%, preferably up to 4 wt.%, and particularly preferably less than 2 wt.%.
  • the invention accordingly also provides a process for the preparation of an L-methionine-containing animal feedstuffs additive from fermentation broths, which comprises the steps
  • auxiliary substances chosen from the group consisting of silicas, silicates, stearates, grits and bran to the substances obtained according to a) to d) for stabilization and, to increase the storability; or
  • L-methionine can be carried out by ion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190).
  • the process according to the invention is used for the fermentative preparation of amino acids, in particular L-methionine.
  • Example 1 The present invention is explained in more detail in the following with the aid of embodiment examples .
  • Example 1 The present invention is explained in more detail in the following with the aid of embodiment examples .
  • the cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Code no. 27-0868-04) .
  • the cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA- Ligase, Code no.27-0870-04) .
  • the ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217) .
  • the plasmid preparation of the recombinant clones was carried out with Biorobot 9600 (Product No. 900200, Qiagen, Hilden, Germany) .
  • the sequencing was carried out by the dideoxy chain termination method of Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A., 74:5463-5467) with modifications according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067).
  • the "RR dRhodamin Terminator Cycle Sequencing Kit” from PE Applied Biosystems Product No. 403044, Rothstadt, Germany) was used.
  • the raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217-231) version 97-0.
  • the individual sequences of the pZerol derivatives were assembled to a continuous contig.
  • the computer-assisted coding region analysis was prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231).
  • the resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading frame of 1046 base pairs, which was called the metF gene. The metF gene codes for a protein of 349 amino acids.
  • metF-EVP5 metF-EVP5: . .
  • the primers shown were synthesized by MWG-Biotech AG.
  • PCR reaction was carried out by the standard PCR method of Innis et al. (PCR protocols. A guide to methods and applications, 1990, Academic Press) with Pwo-Polymerase from Roche Diagnostics GmbH (Mannheim, Germany) .
  • the primers allow amplification of a DNA fragment 792 bp in size, which carries the complete metF gene, which is suitable for expression.
  • the primer metF-EVP5 contains the sequence for the cleavage site of the restriction endonuclease BamHI and the primer metF-EVP3 the cleavage site of the restriction endonuclease Xhol, which are marked by underlining in the nucleotide sequence shown above.
  • the metF fragment 792 bp in size was cleaved with the restriction endonucleases BamHI and Xhol.
  • the batch was separated by gel electrophoresis and the metF fragment was then isolated from the agarose gel with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
  • the E. coli - C. glutamicum shuttle expression vector pZ8-l (EP 0 375 889) was used as the base vector for the expression.
  • DNA of the plasmid pZ8-l was cleaved completely with the restriction enzymes BamHI and Sail and then dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250) .
  • the metF fragment isolated from the agarose gel in example 3.1 and cleaved with the restriction endonucleases BamHI and Xhol was mixed with the vector pZ8-l prepared in this way and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA- Ligase, Code no.27-0870-04) . . .
  • the ligation batch was transformed in the E. coli strain DH5 ⁇ mcr (Hanahan, In: DNA cloning. A Practical Approach. Vol. I. IRL-Press, Oxford, Washington DC, USA) . Selection of plasmid-carrying cells was made by plating out the transformation batch on LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/1 kanamycin. After incubation overnight at 37°C, recombinant individual clones were selected. Plasmid DNA was isolated from a transformant with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and checked by restriction cleavage. The resulting plasmid was called pCREmetF. 3.3 Preparation of the strain C. glutamicum ATCC13032/pCREmetF
  • the vector pCREmetF obtained in example 3.2 was electroporated in the strain C. glutamicum ATCC13032 using the electroporation method described by Liebl et al. (FEMS Microbiology Letters, 53:299-303 (1989)). Selection of the plasmid-carrying cells took place on LBHIS agar comprising 18.5 g/1 brain-heart infusion broth, 0.5 M sorbitol, 5 g/1 Bacto-tryptone, 2.5 g/1 Bacto-yeast extract, 5 g/1 NaCl and 18 g/1 Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
  • Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology 144, 915-927) and checked by restriction cleavage. The resulting strain was called ATCC13032pCREmetF.
  • the C. glutamicum strain ATCCl3032/pCREmetF obtained in example 3 was cultured in a nutrient medium suitable for the production of methionine and the methionine content in the culture supernatant was determined.
  • the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/1) ) for 24 hours at 33°C.
  • a preculture was seeded (10 ml medium in a 100 ml conical flask) .
  • the medium MM was used as the medium for the preculture.
  • Medium MM
  • MOPS morpholinopropanesulfonic acid
  • Vitamin B12 (sterile-filtered) 0.02 mg/1
  • the CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved.
  • the sterile substrate and vitamin solutions were then added, as well as the CaC0 3 autoclaved in the dry state.
  • Kanamycin (25 mg/1) was added to this.
  • the preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine.
  • a main culture was seeded from this preculture such that the initial OD (660 nm) of the main culture was 0.1.
  • Medium MM was also used for the main culture. Culturing is carried out in a 10 ml volume ⁇ n a 100 ml conical flask with baffles. Kanamycin (25 mg/1) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.
  • the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Kunststoff) .
  • the amount of methionine formed was determined with an amino acid analyzer from Eppendorf- BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.
  • Km Resistance gene for kanamycin
  • metF metF gene of C. glutamicum
  • Ser Arg lie Ala Arg Arg Leu Ala Lys Gin Pro Leu Thr Thr Leu Val 100 105 110 cac ctg ace ctg gtt aac cac act cgc gaa gag atg aag gca att ctt 682
  • Ser Arg lie Ala Arg Arg Leu Ala Lys Gin Pro Leu Thr Thr Leu Val 100 105 110 His Leu Thr Leu Val Asn His Thr Arg Glu Glu Met Lys Ala lie Leu 115 120 125
  • Phe Arg Glu Phe Asp Leu Gly lie Ala Ser Phe Pro Glu Gly His Phe 180 185 190 Arg Ala Lys Thr Leu Glu Glu Asp Thr Lys Tyr Thr Leu Ala Lys Leu 195 200 205

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Sustainable Development (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to an isolated polynucleotide comprising a polynucleotide sequence chosen from the group consisting of a) polynucleotide which is identical to the extent of at least 70 % to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2, b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2, c) polynucleotide which is complementary to the polynucleotides of a) or b), and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c), and processes for the fermentative preparation of L-amino acids using coryneform bacteria in which at least the metF gene is present in enhanced form, and the use of the polynucleotide sequences as hybridization probes.

Description

Nucleotide sequences which code for the metF gene
Field of the Invention
The invention provides nucleotide sequences from coryneform bacteria which code for the etF gene and a process for the fermentative preparation of amino acids, in particular L- methionine, using bacteria in which the metF gene is enhanced.
Prior Art
L-Amino acids, in particular L-methionine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.
It is known that amino acids are prepared by fermentation from strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the methionine analogue α- methyl-methionine, ethionine, norleucine, N- acetylnorleucine, S-trifluoromethylhomocysteine, 2-amino-5- heprenoitic acid, seleno-methionine, ethionine- sulfoximine, methoxine, 1-aminocyclopentane-carboxylic acid, or are auxotrophic for metabolites of regulatory importance and produce amino acid, such as e.g. - methionine, are obtained in this manner.
Methods of the recombinant DNA technique have also been employed for some years for improving the strain of
Corynebacterium strains which produce L-amino acid, by amplifying individual amino acid biosynthesis genes and investigating the effect on the amino acid production.
Object of the Invention
The inventors had the object of providing new measures for • improved fermentative preparation of amino acids, in particular L-methionine.
Summary of the Invention
When L-methionine or methionine are mentioned in the following, the salts, such as e.g. methionine hydrochloride or methionine sulfate are also meant by this.
The invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the metF gene, chosen from the group consisting of
a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID.No. 2,
b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,
c) polynucleotide which is complementary to the polynucleotides of a) or b) , and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c),
the polypeptide preferably having the activity of methylene tetrahydrofolate reductase.
The invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:
(i) the nucleotide sequence shown in SEQ ID No. 1, or
(ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
(iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii) , and optionally
(iv) sense mutations of neutral function in (i) .
The invention also provides
a polynucleotide comprising the nucleotide sequence as shown in SEQ ID No. 1,
a polynucleotide which codes for a polypeptide which comprises the amino acid sequence as shown in SEQ ID No. 2,
a vector containing the polynucleotide according to the invention, in particular a shuttle vector or plasmid vector, and
and coryneform bacteria serving as the host cell, which contain the vector or in which the metF gene is enhanced. The invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library, which comprises the complete gene with the polynucleotide sequence corresponding to SEQ ID No. 1, with a probe which comprises the sequence of the polynucleotide mentioned, according to SEQ ID No. 1 or a fragment thereof, and isolation of the DNA sequence mentioned.
Detailed Description of the Invention
Polynucleotides which comprise the sequences according to the invention are suitable as hybridization probes for RNA, cDNA and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for methylene tetrahydrofolate reductase or to isolate those nucleic acids or polynucleotides or genes which have a high similarity of sequence to methylene tetrahydrofolate reductase.
Polynucleotides which comprise the sequences according to the invention are furthermore suitable as primers with the aid of which DNA of genes which code for methylene tetrahydrofolate reductase can be prepared by the polymerase chain reaction (PCR) .
Such oligonucleotides which serve as probes or primers comprise at least 30, preferably at least 20, very particularly preferably at least 15 successive nucleotides. Oligonucleotides which have a length of at least 40 or 50 nucleotides are also suitable. Oligonucleotides with a length of at least 100, 150, 200, 250 or 300 nucleotides are optionally also suitable.
"Isolated" means separated out of its natural environment. "Polynucleotide" in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA or DNA or modified RNA or DNA.
"Polypeptides" are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.
The polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of methylene tetrahydrofolate reductase, and also those which are at least 70%, preferably at least 80% and in particular which are at least 90% to 95% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.
The invention moreover provides a process for- the fermentative preparation of amino acids, in particular L- methionine, using coryneform bacteria which in particular already produce amino acids, and in which the nucleotide sequences which code for the metF gene are enhanced, in particular over-expressed.
The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or using a gene which codes for a corresponding enzyme having a high activity, and optionally combining these measures.
By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on the starting microorganism.
The microorganisms which the present invention provides can prepare L-amino acids, in particular L-methionine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of coryneform bacteria, in particular of the genus Corynebacterium. Of the genus Corynebacterium, there may be mentioned in particular the species
Corynebacterium glutamicum, which is known among experts for its ability to produce L-amino acids.
Suitable strains of the genus Corynebacterium, in particular of the species Corynebacterium glutamicum (C. glutamicum) , are in particular the known wild-type strains
Corynebacterium glutamicum ATCC13032 Corynebacterium acetoglutamicum ATCC15806 Corynebacterium acetoacidophilum ATCC13870 Corynebacterium thermoaminogenes FERM BP-1539 Corynebacterium melassecola ATCC17965
Brevibacterium flavum ATCC14067 Brevibacterium lactofermentum ATCC13869 and Brevibacterium divaricatum ATCC14020
or L-amino acid-producing mutants or strains prepared therefrom, such as, for example, the L-methionine-producing strain
Corynebacterium glutamicum ATCC21608.
The new metF gene from C. glutamicum which codes for the enzyme methylene tetrahydrofolate reductase [EC: 1.7.99.5] has been isolated.
To isolate the metF gene or also other genes of C. glutamicum, a gene library of this microorganism is first set up in Escherichia coli (E. coli) . The setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: Gene und Klone, Eine Einfϋhrung in die Gentechnologie (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example. A well-known gene library is that of- the E. coli K-12 strain W3110 set up in λ vectors by Kohara et al. (Cell 50, 495 -508 (1987)). Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of C. glutamicum ATCC13032, which was set up with the aid of the cosmid vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in the E. coli K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575).
Bδrmann et al. (Molecular Microbiology 6(3), 317-326) (1992) )~ in turn describe a gene library of C. glutamicum ATCC13032 using the cosmid pHC79 (Hohn and Collins, Gene 11, 291-298 (1980) ) .
To prepare a gene library of C. glutamicum in E. coli it is also possible to use plasmids such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268). Suitable hosts are, in particular, those E. coli strains which are restriction- and recombination- defective. An example of these is the strain DH5αmcr, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649). The long DNA fragments cloned with the aid of cos ids can in turn be subcloned in the usual vectors suitable for sequencing and then sequenced, as is described e.g. by Sanger et al. (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977) .
The resulting DNA sequences can then be investigated with known algorithms or sequence analysis programs, such as e.g. that of Staden (Nucleic Acids Research 14, 217- 232(1986)), that of Marck (Nucleic Acids Research 16, 1829- 1836 (1988)) or the GCG program of Butler (Methods of Biochemical Analysis 39, 74-97 (1998)). The new DNA sequence of C. glutamicum which codes for the metF gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found. The amino acid sequence of the corresponding protein has furthermore been derived from the present DNA sequence by the methods described above. The resulting amino acid sequence of the metF gene product is shown in SEQ ID No. 2.
Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention. In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Conservative amino acid exchanges, such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function.
It is furthermore known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the function thereof. Information in this context can be found by the expert, inter alia, in Ben- Bassat et al. (Journal of Bacteriology 169:751-757 (1987)), in 0' Regan et al. (Gene 77:237-251 (1989)), in Sahin-Toth et al. (Protein Sciences 3:240-247 (1994)), in Hochuli et al. (Bio/Technology 6:1321-1325 (1988)) and in known textbooks of genetics and molecular biology. Amino acid sequences which result in a corresponding manner from SEQ ID No. 2 are also a constituent of the invention.
In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Finally, DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention. Such oligonucleotides typically have a length of at least 15 nucleotides. Instructions for identifying DNA sequences by means of hybridization can be found by the expert, inter alia, in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) and in Liebl et al. (International Journal of Systematic Bacteriology (1991) 41: 255-260) . Instructions for amplification of DNA sequences with the aid of the polymerase chain reaction (PCR) can be found by the expert, inter alia, in the handbook by Gait: Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, UK, 1984) and in Newton and Graham: PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994) .
It has been found that coryneform bacteria produce amino acids, in particular L-methionine, in an improved manner after over-expression of the metF gene.
To achieve an over-expression, the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated. Expression cassettes which are incorporated upstream of the structural gene act in the same way. By inducible promoters, it is additionally possible to increase the expression in the course of fermentative L-methionine production. The expression is likewise improved by measures to prolong the life of the m-RNA. Furthermore, the enzyme activity is also increased by preventing the degradation of the enzyme protein. The genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an over- expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.
Instructions in this context can be found by the expert, inter alia, in Martin et al. (Bio/Technology 5, 137-146 (1987)), in Guerrero et al. (Gene 138, 35-41 (1994)), Tsuchiya and Morinaga (Bio/Technology 6, 428-430 (.1988)), in Eik anns et al. (Gene 102, 93-98 (1991)), in European Patent Specification 0 472 869, in US Patent 4,601,893, in Schwarzer and Pϋhler (Bio/Technology 9, 84-87 (1991), in Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)), in LaBarre et al. (Journal of Bacteriology 175, 1001-1007 (1993)), in Patent Application WO 96/15246, in Malumbres et al. (Gene 134, 15 - 24 (1993)), in Japanese Laid-Open Specification JP-A-10-229891, in Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195 (1998)), in Makrides (Microbiological Reviews 60:512-538 (1996)) and in known textbooks of genetics and molecular biology.
By way of example, for enhancement the metF gene according to the invention was over-expressed with the aid of episomal plasmids. Suitable plasmids are those which are • replicated in coryneform bacteria. Numerous known plasmid vectors, such as e.g. pZl (Menkel et al., Applied and Environmental Microbiology (1989) 64: 549-554), pEKExl (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-l (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBLl or pGAl . Other plasmid vectors, such as e.g. those based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al., FEMS Microbiology Letters 66, 119- 124 (1990)), or pAGl (US-A 5,158,891), can be used in the same manner.
Plasmid vectors which are furthermore suitable are also those with the aid of which the process of gene amplification by integration into the chromosome can be used, as has been described, for example, by Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)) for duplication or amplification of the hom-thrB operon. In this method, the complete gene is cloned in a plasmid vector which can replicate in a host (typically E. coli) , but not in C. glutamicum. Possible vectors are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pKlδmob or pK19mob (Schafer et al., Gene 145, 69- 73 (1994)), pGEM-T (Promega corporation, Madison, WI, USA), PCR2.1-TOPO (Shuman (1994). Journal of Biological Chemistry 269:32678-84; US-A 5, 487, 993) , ρCR®Blunt (Invitrogen,
Groningen, Holland; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)), pEMl (Schrumpf et al, 1991, Journal of Bacteriology 173:4510-4516) or pBGS8 (Spratt et al.,1986, Gene 41: 337-342). The plasmid vector which contains the gene to be amplified is then transferred into the desired strain of C. glutamicum by conjugation or transformation. The method of conjugation is described, for example, by Schafer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods for transformation are described, for example, by Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of a "cross over" event, the resulting strain contains at least two copies of the gene in question.
In addition, it may be advantageous for the production of amino acids, in particular L-methionine, to enhance one or more enzymes of the particular biosynthesis pathway, of glycolysis, of anaplerosis, of the citric acid cycle or of amino acid export, in addition to the metF gene.
Thus for the preparation of amino acids, in particular L- methionine, one or more genes chosen from the group consisting of
• the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
• the tpi gene which codes for triose phosphate isomerase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086), • the pgk gene which codes for 3-phosphoglycerate kinase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
• the pyc gene which codes for pyruvate carboxylase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
• the lysC gene which codes for a feed-back resistant aspartate kinase (ACCESSION NUMBER P26512 ; EP-B-0387527; EP-A-0699759) ,
• the metA gene which codes for homoserine 0- acetyltransferase (ACCESSION Number AF052652),
• the metB gene which codes for cystathionine gamma- synthase (ACCESSION Number AF126953) ,
• the aecD gene which codes for cystathionine gamma-lyase (ACCESSION Number M89931)
• the glyA gene which codes for serine hydroxymethyltransferase (JP-A-08107788) ,
• the etY gene which codes for O-acetylhomoserine sulfhydrylase (DSM 13556)
can be enhanced, in particular over-expressed.
It may furthermore be advantageous for the production of amino acids, in particular L-methionine, in addition to the enhancement of the metF gene, for one or more genes chosen from the group consisting of
• the thrB gene which codes for homoserine kinase (ACCESSION Number P08210) ,
• the ilvA gene which codes for threonine dehydratase (ACCESSION Number Q04513) ,
• the thrC gene which codes for threonine synthase
(ACCESSION Number P23669) , the ddh gene which codes for meso-diaminopimelate D- dehydrogenase (ACCESSION Number Y00151) ,
the pck gene which codes for phosphoenol pyruvate carboxykinase (DE 199 50 409.1; DSM 13047),
the pgi gene which codes for glucose 6-phosphate isomerase (US 09/396,478; DSM 12969),
• the poxB gene which codes for pyruvate oxidase (DE: 1995 1975.7; DSM 13114)
to be attenuated, in particular for the expression thereof to be reduced.
The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter' or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein) , and optionally combining these measures.
By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein.
In addition to over-expression of the metF gene it may furthermore be advantageous, for the production of amino acids, in particular L-methionine, to eliminate undesirable side reactions, (Nakayama: "Breeding of Amino Acid Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982) .
The microorganisms prepared according to the invention can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of amino acids, in particular L- methionine. A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einfiihrung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991) ) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994) ) .
The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).
Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substance can be used individually or as a mixture.
Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.
Organic and inorganic sulfur-containing compounds, such as, for example, sulfides, sulfites, sulfates and thiosulfates, can be used as a source of sulfur, in particular for the preparation of methionine. Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium- containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of metals, such as e. g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the above-mentioned substances. Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.
Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, such as e.g. antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the. desired product has formed. This target is usually reached within 10 hours to 160 hours.
The fermentation broths obtained in this way, in particular containing L-methionine, usually have a dry weight of 7.5 to 25 wt.% and contain L-methionine. It is furthermore also advantageous if the fermentation is conducted in a sugar- limited procedure at least at the end, but in particular over at least 30% of the duration of the fermentation. That is to say, the concentration of utilizable sugar in the fermentation medium is reduced to ≥ 0 to 3 g/1 during this period.
The fermentation broth prepared in this manner, in particular containing L-methionine, is then further processed. Depending on requirements, all or some of the biomass can be removed from the fermentation broth by separation methods, such as e.g. centrifugation, filtration, decanting or a combination thereof, or it can be left completely in this. This broth is then thickened or concentrated by known methods, such as e.g. with the aid of a rotary evaporator, thin film evaporator, falling film evaporator, by reverse osmosis, or by nanofiltration. This concentrated fermentation broth can then be worked up by methods of freeze drying, spray drying, spray granulation or by other processes to give a preferably free-flowing, finely divided powder.
This free-flowing, finely divided powder can then in turn by converted by suitable compacting or granulating processes into a coarse-grained, readily free-flowing, storable and largely dust-free product. In the granulation or compacting it is advantageous to employ conventional organic or inorganic auxiliary substances or carriers, such as starch, gelatin, cellulose derivatives or similar substances, such as are conventionally used as binders, gelling agents or thickeners in foodstuffs or feedstuffs processing, or further substances, such as, for example, silicas, silicates or stearates.
"Free-flowing" is understood as meaning powders which flow unimpeded out of the vessel with the opening of 5 mm (millimeters) of a series of glass outflow vessels with outflow openings of various sizes (Klein, Seifen, Ole, Fette, Wachse 94, 12 (1968)).
As described here, "finely divided" means a powder with a predominant content (> 50 %) with a particle size of 20 to
Hi H- H σ CO Ω c rt H- "3 _ TJ Ω CO Φ SD (D > O
Φ 3 Hi M rt D> O 3" rt μ- σ 0 C X 3 3 H s^
H o 1 S H H- Φ 3 H- o 3 iQ SD rt σ
3 l-i rt o H t 3 μ- ID Φ Ω <! S 3 0 Φ CO
Φ iQ " 1 Ω o iQ CO O -* Φ Φ H TJ Ω H H ft
3 fu Φ J*-. 3J 3 rt s CO 3 O μ- o iQ 3 (D rt 3 φ f Hi O CO & CO rt Φ 3 £U (D 3
ID H- σ O CO rt H- 3 rt tr φ μ- O <! 3 rt rt rt Ω H- O » Φ (- (D £D (-• O o H Φ μ- μ- μ-
H- o U_> CO 3 Ω tr rt φ 3 CO 3 Ω <! SD
O co 3 N> iQ 1 tr (- ff μ- SD O μ- rt Φ
3 o SD O 3 Hi Φ φ + 3 μ-* rt μ- o
M CO • 3 CO O o 3^ μ- O l-S * H
H- CO CO H- Hi rt TJ S rt rt Φ Ω 3 ^ o
SD a 3 O l-S μ- 3" " H SD SD μ- CO ι-> CO H- SD H- H- H o co μ- μ- CO CO μ- 3 3* O
Φ ^ CO 3 Ω 3 3 α α Ω CO Ω ^ o O
P. 0) iQ 3 μ- c 3* μ- h Z _— >
H- Hi CO O H- iQ Ω Hi Ω Φ SD CO 3 iQ Φ Λ
3 o φ Ω SD 3 Φ rt C O 3 3 μ- SD <!
H TJ Φ iQ O) O rt 3 Φ M H) 3 Φ (Jl Q cu CO Φ 3 rt Ω rt rt H \ μ- φ μ- H o\°
Φ φ H H- H- 3 rt H- SD Φ Φ CO o Ω φ Ω ^
3 X ID £ H rt CO O 3 h ; H SD O.
Φ 0) rt l-1 H- O *% 3 ti¬ rt O ti¬ CQ Ω rt o
H 3 Φ O Ω ^ σ ro l-S 3 ro rt (D 3* Hi
0) TJ O JD σ tr Φ Ω SD μ- CD H Φ
;— H Φ rt CO : 3" H σ X Hi H 3 φ O Φ 3 σ 3 Φ μ- φ Hi μ- TJ φ
H Hi Φ CO Ω Ω 0) H μ- 3 o. iQ CO φ H rt
Φ SD H rt *«* 3- o 3 o ?v l-S H O 3*
3 3* cu μ- β Φ Φ £U μ- TJ μ- o Φ SD SD rt 3 iQ I-1 CO H 3 rt l-S CO c o
<1 Φ H l-1 O μ- Q) tr ω Ω CO a. co O 0 Ω 3
Φ H ω iQ " 3 rt IV) H • Ω tr rt μ- α H- H- iQ μ- CO Φ CO 3
• 3 3 Hi CO μ- ^-^ σ α rt σ CO rt Ω Φ d vQ DJ SD o Ό rt 3 φ to SD μ, CO SD SD
H l-S CO rt H H O rt IΛ α Φ σ SD μ- 3 3 o
3 H- rt Φ O 3 O <i> μ- 3 3 Ω o
3 tr CO Φ Ω CU Cπ μ- Φ M CO iQ Φ tr Ω
(D iQ Φ Φ ** X Φ Ω SD * — 3 tx μ- •*« ^ φ C
0. CO u CO tr SD N Z h α rt TJ Ω CO 3 CO CO CO α-> rt 3 φ 3 CO tr (D l-S
H- tr H H rt TJ Φ rt < > tr TJ α ro S^ μ- σ μ- rt φ O μ- Φ M CO SD φ H SD Ω Ω CO 3
H- Ω tr SD φ μ- rt Φ z 3^ " o u3 o Φ Φ i-s . — . 3 Φ T CO μ- CO H •
^ 3 CO α 0J z 0J μ- rt SD μ- σ
CO rt 3 Ω T μ- iQ rt SD 3* CO Cfl φ
H- Φ Φ O SD 3 ro φ 3 O *^ rt K ft α
3 ω rt fϋ n tr Hi OJ rt rt Z 00 (D SD Hi 3 0
Φ £ H- μ- tr » rt H O o 3
H 3 Ω H- c Ω H s: rt iQ e Ω — * H - 3 rt * 3 3^ • φ Φ o
Φ (D O
H h
CO u> t r μ> μ-
Cπ σ cπ o en o cn
ID TJ o fD 3 f-3 3 Ω μ- Ω iQ Hi
0- H H I-1 Φ tr 3 O 3 μ- hi 3 o O rt Φ ti¬ 3 Ω rt O hi φ Ω TJ o 3* CO ll J μ- H 3 rt α Φ 3 μ- Φ μ- 0 3 μ- TJ tr O l-S tr o rt 3 Ω CO Φ μ- CO φ ro 3 o μ- 3 φ *« H
3 μ- H o SD 3 O CO £1) 3 ιΩ 3 O CO Ω O O μ- rt 3 ro SD ID 3 μ- 3 hi
<j Φ tr 3 μ- SD iQ Ω Φ μ- TJ O Φ SD μ- H SD • tr
• (1- 3 Ω < ro H O
3 CU Q> SD CO 3 SD H
SD t-3 3 CO μ- 0 CD O iQ - Ω O 3 3 TJ ** SD h-1 Φ Φ Φ i-S σ ro rt CO μ- 3
CO TJ CO μ- 3 Ω Hi μ-
Φ μ- Φ rt rt o o Ω o Ω
O 3 3 3^ SD Hi 3 * SD l-S h 0 ro 3 SD Ω SD
H CO μ- O rt 1-- SD μ- ro Ω
SD iQ o 3 n ro 3" H ω X μ-
CO SD μ- iQ (D O ro "* SD Q.
3 μ- Ω ^ o 3 CD
3 μ- O ro J α Hi hf TJ μ- Ω 3 3 μ- H ro O Z
X o μ- 3 o CO H Hi Φ tr rt CO l-S H Ω Ω μ- 3 ^ μ-
3 3 ro μ-* c H Φ 3 Ω
H tr H uO. 3 3 Ω ro SD CU 3"
Φ CO μ- 3 μ- α rt Q) H Ω
CO ft ►Q μ- X μ- • 3 μ- ro Ω
SD 3 H rt 3 μ- TJ Ω rt CD rt 3 μ- ro 3 iQ Hi μ- hi
0 Ω 3 hi ro (D Ω hi
Φ ro ro tr1 rt Ω rt CO Hi 3 1 3" μ- SD tr o rt D 3 ro ti¬ Ω 0 ro 3 H o ro <; ll μ- 3 φ 3 tr* rt ro Φ
1 3 1 T μ- t •^ *» ro rt CD 3 μ- 3 cu μ- rt
CO μ- 3 co ro 0 TJ H 3 O
3 0 H rt 3 n O SD SD
M 3 μ- cu 3- μ- o CO μ** Ω rt rt Φ 3 μ- 3 <J ro μ- rt * μ- iQ Ω o ro ro • μ- hi
3 O 3 ^ Ω ro iQ Ω SD 3 μ- SD rt 1-3 Φ
(D Ω 3 3 3* ff rt CD
0 3 - CO Φ ro ro ro " Ω Ω
3 3 --» co ro μ- CD tr μ- rt o ro : H
Φ rt H Ω tr
SD SD SD CD o tr ti¬ 3 σ μ- X μ-* ro 1 CO •-< φ o μ<
concentrated fermentation broth, or also during the drying or granulation process. It is likewise possible to add an organic substance or a mixture of several organic substances to the fermentation broth and a further organic substance or a further mixture of several organic substances during a later process step, for example granulation.
-The product described above is suitable as a feedstuffs additive, i.e. feed additive, for animal nutrition.
The L-methionine content of the animal feedstuffs additive is conventionally 1 wt.% to 80 wt.%, preferably 2 wt.% to 80 wt.%, particularly preferably 4 wt.% to 80 wt.%, and very particularly preferably 8 wt.% to.80 wt.%, based on the dry weight of the animal feedstuffs additive. Contents of 1 wt.% to 60 wt.%, 2 wt.% to 60 wt . %', 4 wt.% to 60 wt.%, 6 wt.% to 60 wt.%, 1 wt.% to 40 wt.%, 2 wt.% to 40 wt.% or 4 wt.% to 40 wt.% are likewise possible. The water content of the feedstuffs additive is conventionally up to 5 wt.%, preferably up to 4 wt.%, and particularly preferably less than 2 wt.%.
The invention accordingly also provides a process for the preparation of an L-methionine-containing animal feedstuffs additive from fermentation broths, which comprises the steps
a) culture and fermentation of an L-methionine-producing microorganism in a fermentation medium;
b) removal of water from the L-methionine-containing fermentation broth (concentration) ;
c) removal of an amount of 0 to 100 wt.% of the biomass formed during the fermentation; and d) drying of the fermentation broth, obtained according to a) and/or b) to obtain the animal feedstuffs additive in the desired powder or granule form.
If desired, one or more of the following steps can furthermore be carried out in the process according to the invention:
e) addition of one or more organic substances, • including L-methionine and/or D-methionine and/or the racemic mixture D, L-methionine, to the products obtained according to a) , b) and/or c) ;
f) addition of auxiliary substances chosen from the group consisting of silicas, silicates, stearates, grits and bran to the substances obtained according to a) to d) for stabilization and, to increase the storability; or
g) conversion of the substances obtained according to a) to e) into a form stable to the animal stomach, in particular rumen, by coating with film-forming agents.
The analysis of L-methionine can be carried out by ion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190).
The process according to the invention is used for the fermentative preparation of amino acids, in particular L-methionine.
The present invention is explained in more detail in the following with the aid of embodiment examples . Example 1
Preparation of a genomic cosmid gene library from Corynebacterium glutamicum ATCC 13032
Chromosomal DNA from Corynebacterium glutamicum ATCC 13032 was isolated as described by Tauch et al . (1995, Plasmid 33:168-179) and partly cleaved with the restriction enzyme Sau3AI (A ersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Code no. 27-0913-02) . The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product
Description SAP, Code no. 1758250) . The DNA of the cosmid vector SuperCosl (Wahl et al. (1987) Proceedings of the National Academy of Sciences USA 84:2160-2164), obtained from Stratagene (La Jolla, USA, Product Description SuperCosl Cosmid Vector Kit, Code no. 251301) was cleaved with the restriction enzyme Xbal (Amersham Pharmacia, Freiburg, Germany, Product Description Xbal, Code no. 27- 0948-02) and likewise dephosphorylated with shrimp alkaline phosphatase.
The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Code no. 27-0868-04) . The cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA- Ligase, Code no.27-0870-04) . The ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217) .
For infection of the E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Research 16:1563-1575) the cells were taken up in 10 mM MgS0 and mixed with an aliquot of the phage suspension. The infection and titering of the cosmid library were carried out as described by Sambrook et al. ω t to I-1 μ- o cn o Cπ o n
TJ φ ro σ tr* cu TJ TJ Ω N M 1-3 ts rt O m T o CO μ- ts rt j H M μ- μ» hi z a hi tO μ*1 μ- Φ SD CO - h-1 ro 3 " μ- μ- tr Φ hi tr hi ro SD 3 μ- 3" tr CQ X ro 3 l£) SD
0 CO φ o μ- tr SD 0 SD Φ hi <! Φ t-1 (D φ TJ 0 o CD CD 3 CD 1 Φ ro 0 SD hi Ω cn hi «3
Ω Ω ti¬ 3 o lΩ α I-. SD o μ- M SD CO Ω Ω O rt α h-1 3 ro 3 cπ tr 00
Φ ω rt ro iQ hi CD 3 3 3 <J rt σ Φ X O hi 3 T 3 H > hi ro ϊO Ω SD TJ tr o IX)
Φ a-. hS Ω CD CD ro Ω SD Φ ω hi s 3 H μ- (D Ω 3' φ μ- H 3 3 μ- 0 rt μ- CO SD hi α CO o 3^ μ- rt Ω 3 rt Ω α CD O H N rt rt SD 3 TJ Ω u CO μ- ro ro rt < — μ- 1 TJ ^ 3 o H rt μ- Ω ιΩ Φ μ- rt rt rt . — , rt TJ 3 O μ- μ- - S
3 o Ω hi μ- CO 2 SD s: ? ro 0 Q o O SD co μ- μ- Q hi μ- 3 t ro o hi o up — - H 3 tr 0 μ- ιΩ 3 Hi ro φ hi 3 Φ CO o 0 Φ Φ Ω 3 0 rt H
CD CD hi tr ro μ- • rt l-S hi H £U CO Φ s; 3 Φ 3 U TJ SD ti¬ tr CD μ- tiro SD S PL 3 " - o _— . ft 3 3 tr Ω Φ H CO 3 σ 3 ro 0 0 ro Ω o 3 ro μ- rt CU r-o hi 3 3" CU H ι H *— H O O SD o 3 α. <i ιΩ 3 rt p. tr Φ 3 tr rt ro rt 3 hi Φ 3 Φ μ- PJ ro SD 3" SD 3 TJ ro Ω μ-
O 3 3 3* 1 μ- 3* 0- o ^ rt ιΩ J O 3 SD 3 •< μ- CO hi ro SD rt . — H CD ro o tr Φ 3 CO - — hj O Φ rt Ω CO 3 α 3 o ro 3 -1 H ff rt ι-3 ιΩ o H" O 3 O μ- φ • CU μ- ff ro > Hi Λ μ- μ» μ-
Φ ff SD <! ^ SD CO σ-i H H " 3 ιΩ o o Φ TJ H TJ TJ μ- S 3 v *• co o ro 3 Φ φ 00 ι ^ Φ 0 ιΩ 3 rt μ> Φ 3 3' -^ ff CD 3 μ- CD ro * μ» h-1
3 Ω O H o ff Λ 1 CD 3 CD φ μ- cπ M α o SD hi 3 3 3 ll- CD σ o
SD M 3' ro 3 o hi 3 o rt μ- 3 3 O o Φ CO μ- CO TJ H (D μ- Ώ o ro 3 rt • ti μ- μ-* o Φ J-. o H 3 ^ Ω 3 o Ω > SD T hi 3 Ω TJ μ- μ- CU — μ- μ- μ- ro 3 ιΩ o 3 — ro μ- n μ- fi¬ TJ ιΩ 3^ O CD •< Ω hi 3 3 rt 3 3
O Ω rt SD tr Ω H Ω ι-3 3 pi rt ll "* 3 O α Ω O Φ 0- ιΩ s: ιΩ ιΩ
3 O 3 rt O μ- 3 rt P 3" <Ω μ- O O O hi 3 μ- Ω H TJ μ- O μ- • • U μ- CU TJ ro 3 >-3 (D μ- μ- CD rt TJ • TJ O •< Ω SD μ- α <J O rt TJ
H μ- μ*1 •s H rt ιΩ * 3 O rt < ro tr hi rt rt ^ ro CD « μ- Hi 3J
• • > μ- μ- ro 3 3 Φ , — . o o 0 μ- CU CU- 3 μ- O CU
> o rt 3 CU <j Φ Ω TI o hi 0- Ω ft 3 **1 <i O rt 3 rt μ> ti¬ h-1
Ω rt μ> 1-3 * ιP H Φ H ro •τ) rt ft hi o Φ 3 O Φ O H Φ Φ SD tr o ro SD
CD H VD 3* Ω μ- TJ 3 H tr O o CO Ω ro a H φ H o α tr
0, u VD μ- ι-3 t rt ιΩ H N O φ hi 0- σ μ- rt O μ- Z TJ ro o
Φ μ- D 4-. SD ^-^ O cu O *< 0- hi 3 T3 ω 3 z to tr z μ- hi Ω 3 Ω 3 o H
3 3 hi μ» hi rt g 3 H T Ω ^ Z σ μ- 3 μ- rt O o ro o ιΩ 3 SD
<. μ- H σ U3 μ- 3 ro Ω SD t i rt s: O w rt 1 ti rt ^ α H rt \ rt rt
O •^ μ- μ- o 00 TJ o Ω rt 3 φ Φ rt • 3" o iQ 3J 3 O «ι ff o o ts P <Ω ιΩ hi <£> N 3 rt ro Q. hi 2 H tr <£> rt Ω 3 μ- o hi
Hi (SI S cu SD — •- Φ SD 2! CO 0 0 Φ φ μ1 s ω μ> rt 3J rt ιΩ 3 CU 3 <
5 CO rt CO * H o α 3 O 1 • SD 3- CO Q * Φ Φ CD 3 O 2 μ- φ S O Hi φ ts • h-1 μ- Ω cn 3 hi 1 ro φ 3 •≤ 3 3 TJ Ir1 2
Ω O 3 o rt o 1 CD H •τ) to ω o 00 3 μ- o μ> 3 O SD ro rt μ- ro CD μ- » μ- 3 ^— . tr μ- rt Ω Pϋ i o o CO to 3* 3 t 3 hi (D CO Ω 3 ro Ω ID ro ro 3* H ^-^ t O o o H 3 cπ Φ TJ — SD φ 3 μ-
. — . μ- CU 3
3 3 3" o Z ro μ- __? cπ σ t cu μ- o μ- • 3 to 3 t μ- 3 H ιΩ (D
Ω cπ O μ- SD α 3 CU TJ o 3 rt h-1 rt — 3 CD ti¬ hh o α. -1 U I-1 ro H tr X H 2 CO Ω rt CD o Ω SD Φ • H 3 ll CU μ1 o μ- μ- hi ^ D SD μ- rt 3 t> CU 0 μ- H 1 rt . μ- o α Hi ?r * μ- Ω o H <! 3
3 o 3 SD H Ω CO o CO 3 lO H > SD ro TJ Ω rt SD μ- __. o α rt μ** H Ω 3 SD 3 3 3" σ φ μ- SD Φ hi ft
• 3 •* ti¬ α tr1 o
Φ μ- μ- O H μ- CU -- — φ cu μ- ( rt H μ- σ O μ- H ro 3 φ h-1
CO IT* SD X hi ro 3 CO ιΩ rt 3 ro 3 3 i3 α o Φ α. SD 3 x
• μ> φ z rt o μ- CD s: Ω Hi Φ 3J φ l-i SD ro c 3 hi μ- μ- ti¬ 3
<£> li¬ cu 3 3 ro 3 SD hi hi 3 3 3 Ω SD ro O O
• I ft O hi μ- ts CO μ- o *• rt i -
** < rt Φ CO vΩ μ- Ω H X TJ σ ro ro 3 H TJ 3 " cn 3 φ rt M
^ H hi rt ιΩ o rt Φ N 3 3" o μ-
CO 3* 3 μ- μ- 3 3 ro rt o 3 '' ro <X5
3 > 3 Φ CO
87:4645-4649) and plated out on LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/1 zeocin.
The plasmid preparation of the recombinant clones was carried out with Biorobot 9600 (Product No. 900200, Qiagen, Hilden, Germany) . The sequencing was carried out by the dideoxy chain termination method of Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A., 74:5463-5467) with modifications according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany) was used. The separation by gel electrophoresis and analysis of the sequencing reaction were carried out in a "Rotiphoresis NF Acrylamide/Bisacrylamide" Gel (29:1) (Product No. A124.1, Roth, Karlsruhe, Germany) with the "ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, Germany) .
The raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217-231) version 97-0. The individual sequences of the pZerol derivatives were assembled to a continuous contig. The computer-assisted coding region analysis was prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231).
The resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading frame of 1046 base pairs, which was called the metF gene. The metF gene codes for a protein of 349 amino acids. Example 3
Preparation of the strain C. glutamicum ATCC13032/pCREmetF
3.1 Amplification of the metF gene
From the strain ATCC13032, chromosomal DNA was isolated by the method of Eikmanns et al. (Microbiology 140: 1817 -1828 (1994)). Starting from the nucleotide sequences of the methionine biosynthesis genes metF (SEQ ID No. 1) of C. glutamicum ATCC13032, the following oligonucleotides were chosen for the polymerase chain reaction (PCR) (see SEQ ID No. 3 and SEQ ID No. 4):
metF-EVP5: . .
5 ' -GATCTAGGATCCAAAGGAGGACAACCATGTCCCTAACGAACATCCC-3 '
metF-EVP3:
5 ' -GATCTACTCGAGTTCTTCTAGTTGGCTCGGCA-3 '
The primers shown were synthesized by MWG-Biotech AG
(Ebersberg, Germany) and the PCR reaction was carried out by the standard PCR method of Innis et al. (PCR protocols. A guide to methods and applications, 1990, Academic Press) with Pwo-Polymerase from Roche Diagnostics GmbH (Mannheim, Germany) . With the aid of the polymerase chain reaction, the primers allow amplification of a DNA fragment 792 bp in size, which carries the complete metF gene, which is suitable for expression.
Furthermore, the primer metF-EVP5 contains the sequence for the cleavage site of the restriction endonuclease BamHI and the primer metF-EVP3 the cleavage site of the restriction endonuclease Xhol, which are marked by underlining in the nucleotide sequence shown above.
The metF fragment 792 bp in size was cleaved with the restriction endonucleases BamHI and Xhol. The batch was separated by gel electrophoresis and the metF fragment was then isolated from the agarose gel with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
3.2 Cloning of metF in the vector p28-l
The E. coli - C. glutamicum shuttle expression vector pZ8-l (EP 0 375 889) was used as the base vector for the expression.
DNA of the plasmid pZ8-l was cleaved completely with the restriction enzymes BamHI and Sail and then dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250) .
The metF fragment isolated from the agarose gel in example 3.1 and cleaved with the restriction endonucleases BamHI and Xhol was mixed with the vector pZ8-l prepared in this way and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA- Ligase, Code no.27-0870-04) . . .
The ligation batch was transformed in the E. coli strain DH5αmcr (Hanahan, In: DNA cloning. A Practical Approach. Vol. I. IRL-Press, Oxford, Washington DC, USA) . Selection of plasmid-carrying cells was made by plating out the transformation batch on LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/1 kanamycin. After incubation overnight at 37°C, recombinant individual clones were selected. Plasmid DNA was isolated from a transformant with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and checked by restriction cleavage. The resulting plasmid was called pCREmetF. 3.3 Preparation of the strain C. glutamicum ATCC13032/pCREmetF
The vector pCREmetF obtained in example 3.2 was electroporated in the strain C. glutamicum ATCC13032 using the electroporation method described by Liebl et al. (FEMS Microbiology Letters, 53:299-303 (1989)). Selection of the plasmid-carrying cells took place on LBHIS agar comprising 18.5 g/1 brain-heart infusion broth, 0.5 M sorbitol, 5 g/1 Bacto-tryptone, 2.5 g/1 Bacto-yeast extract, 5 g/1 NaCl and 18 g/1 Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology 144, 915-927) and checked by restriction cleavage. The resulting strain was called ATCC13032pCREmetF.
Example 4
Preparation of methionine with the strain C. glutamicum ATCC13032/pCREmetF
The C. glutamicum strain ATCCl3032/pCREmetF obtained in example 3 was cultured in a nutrient medium suitable for the production of methionine and the methionine content in the culture supernatant was determined.
For this, the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/1) ) for 24 hours at 33°C. Starting from this agar plate culture, a preculture was seeded (10 ml medium in a 100 ml conical flask) . The medium MM was used as the medium for the preculture. Medium MM
CSL (corn steep liquor) 5 g/1
MOPS (morpholinopropanesulfonic acid) 20 g/1
Glucose (autoclaved separately) 50g/l
Salts:
(NH4)2S04 25 g/1
KH2P04 0.1 g/1
MgS04 * 1 H20 1.0 g/1
CaCl2 *.2 H20 10 mg/1
FeS0 * 7 H20 . 10 mg/1
MnS04 * H20 5.0mg/l
Biotin (sterile-filtered) 0.01 mg/1
Vitamin B12 (sterile-filtered) 0.02 mg/1
Thiamine * HC1 (sterile-filtered) 0.2 mg/1
CaC03 25 g/1
The CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved. The sterile substrate and vitamin solutions were then added, as well as the CaC03 autoclaved in the dry state.
Kanamycin (25 mg/1) was added to this. The preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine. A main culture was seeded from this preculture such that the initial OD (660 nm) of the main culture was 0.1. Medium MM was also used for the main culture. Culturing is carried out in a 10 ml volumeάn a 100 ml conical flask with baffles. Kanamycin (25 mg/1) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.
After 72 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich) . The amount of methionine formed was determined with an amino acid analyzer from Eppendorf- BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.
The result of the experiment is shown in Table 1.
Table 1
Brief Description of the Figure:
■ Figure 1: Plasmid pCREmetF
The abbreviations used have the following meaning:
Km: Resistance gene for kanamycin
metF: metF gene of C. glutamicum
Ptac: tac promoter
TI T2: Terminator T1T2 of the rrnB gene of E. coli
rep: Plasmid-coded replication origin for C. glutamicum (of pHM1519) BamHI: Cleavage site of the restriction enzyme BamHI
Sail: Cleavage site of the restriction enzyme Sail
SEQUENCE PROTOCOL
<110> Degussa AG
<120> Nucleotide sequences which code for the metF gene
<130> 000363 BT
<140> <141>
<160> 4
<170> Patentln Ver. 2.1
<210> 1
<211> 1551
<212> DNA
<213> Corynebacterium glutamicum
<220>
<221> CDS
<222> (299) .. (1345)
<223> metF gene
<400> 1 gcgtcaagga cggactcaag tttttcagaa gaattcttat ggccttgcgc cgccaggaaa 60 ccagcccacg cataaagagg acggattcgc tttcctccat tgagcacgaa actgcgaaga 120 tgggccacag catctgtgac aggagcgccg atatcagcaa ttgttagctc ttgagcatcg 180 aggaactgcg tcaaacgatc tcgcacgacc tccggaaatt tgtcgaggtc aaggtcatgg 240 gcatcgaaac tgctcaagga gacgtccttc aatcgaatag ggggatgcgg gctgaatt 298 ttg gtg gag gtg aat aaa tgc cag agg cag tec caa caa aac act etc 346 Met Val Glu Val Asn Lys Cys Gin Arg Gin Ser Gin Gin Asn Thr Leu 1 5 10 15 ate aca eta aga tac cca ggc atg tec eta acg aac ate cca gee tea 394 lie Thr Leu Arg Tyr Pro Gly Met Ser Leu Thr Asn lie Pro Ala Ser 20 25 30 tct caa tgg gca att age gac gtt ttg aag cgt cct tea ccc ggc cga 442 Ser Gin Trp Ala lie Ser Asp Val Leu Lys Arg Pro Ser Pro Gly Arg 35 40 45 gta cct ttt tct gtc gag ttt atg cca ccc cgc gac gat gca get gaa 490 Val Pro Phe Ser Val Glu Phe Met Pro Pro Arg Asp Asp Ala Ala Glu 50 55 60 gag cgt ctt tac cgc gca gca gag gtc ttc cat gac etc ggt gca teg 538 Glu Arg Leu Tyr Arg Ala Ala Glu Val Phe His Asp Leu Gly Ala Ser 65 70 75 80 ttt gtc tec gtg act tat ggt get ggc gga tea ace cgt gag aga ace 586 Phe Val Ser Val Thr Tyr Gly Ala Gly Gly Ser Thr Arg Glu Arg Thr 85 90 95 tea cgt att get cga cga tta gcg aaa caa ccg ttg ace act ctg gtg 634
Ser Arg lie Ala Arg Arg Leu Ala Lys Gin Pro Leu Thr Thr Leu Val 100 105 110 cac ctg ace ctg gtt aac cac act cgc gaa gag atg aag gca att ctt 682
His Leu Thr Leu Val Asn His Thr Arg Glu Glu Met Lys Ala lie Leu 115 120 125 egg gaa tac eta gag ctg gga tta aca aac ctg ttg gcg ctt cga gga 730 Arg Glu Tyr Leu Glu Leu Gly Leu Thr Asn Leu Leu Ala Leu Arg Gly 130 135 140 gat ccg cct gga gac cca tta ggc gat tgg gtg age aec gat gga gga 778 Asp Pro Pro Gly Asp Pro Leu Gly Asp Trp Val Ser Thr Asp Gly Gly 145 150 155 160 ctg aac tat gee tct gag etc ate gat ctt att aag tec act cct gag 826 Leu Asn Tyr Ala Ser Glu Leu lie Asp Leu lie Lys Ser Thr Pro Glu 165 170 175 ttc egg gaa ttc gac etc ggt ate gee tec ttc ccc gaa ggg cat ttc 874
Phe Arg Glu Phe Asp Leu Gly lie Ala Ser Phe Pro Glu Gly His Phe
180 185 190 egg gcg aaa act eta gaa gaa gac aec aaa tac act ctg gcg aag ctg 922
Arg Ala Lys Thr Leu Glu Glu Asp Thr Lys Tyr Thr Leu Ala Lys Leu 195 200 205 cgt gga ggg gca gag tac tec ate acg cag atg ttc ttt gat gtg gaa 970 Arg Gly Gly Ala Glu Tyr Ser lie Thr Gin Met Phe Phe Asp Val Glu 210 215 220 gac tac ctg cga ctt cgt gat cgc ctt gtc get gca gac ccc att cat 1018 Asp Tyr Leu Arg Leu Arg Asp Arg Leu Val Ala Ala Asp Pro lie His 225 230 235 240 ggt gcg aag cca ate att cct ggc ate atg ccc att ace gag ctg egg 1066 Gly Ala Lys Pro lie lie Pro Gly lie Met Pro lie Thr Glu Leu Arg 245 250 255 tct gtg cgt cga cag gtc gaa etc tct ggt get caa ttg ccg age caa 1114
Ser Val Arg Arg Gin Val Glu Leu Ser Gly Ala Gin Leu Pro Ser Gin
260 265 270 eta gaa gaa tea ctt gtt cga get gca aac ggc aat gaa gaa gcg aac 1162
Leu Glu Glu Ser Leu Val Arg Ala Ala Asn Gly Asn Glu Glu Ala Asn 275 280 285 aaa gac gag ate cgc aag gtg ggc att gaa tat tec aec aat atg gca 1210 Lys Asp Glu lie Arg Lys Val Gly lie Glu Tyr Ser Thr Asn Met Ala 290 295 300 gag cga etc att gcc gaa ggt gcg gaa gat ctg cac ttc atg acg ctt 1258 Glu Arg Leu lie Ala Glu Gly Ala Glu Asp Leu His Phe Met Thr Leu 305 310 315 320 aac ttc aec cgt gca ace caa gaa gtg ttg tac aac ctt ggc atg gcg 1306 Asn Phe Thr Arg Ala Thr Gin Glu Val Leu Tyr Asn Leu Gly Met Ala 325 330 335 cct get tgg gga gca gag cac ggc caa gac gcg gtg cgt taagccctct 1355 Pro Ala Trp Gly Ala Glu His Gly Gin Asp Ala Val Arg 340 345 taggaatcat gaagggggag ggcggtgate aatacggeaa acggeegttg atceccgtca 1415 aacctaaact gcetgageaa gtcagtgaag ccgagagage gataeaggct aaacgeatgg 1475 ttcgcetcat cgtcgacctc gggtgtagae aaaatggcaa aagtgttttg tttgtetttt 1535 aacagttcat gcatca 1551
<210> 2
<211> 349 <212> PRT
<213> Corynebacterium glutamicum
<400> 2
Met Val Glu Val Asn Lys Cys Gin Arg Gin Ser Gin Gin Asn Thr Leu 1 5 10 15 lie Thr Leu Arg Tyr Pro Gly Met Ser Leu Thr Asn lie Pro Ala Ser 20 . 25 30 Ser Gin Trp Ala lie Ser Asp Val Leu Lys Arg Pro Ser Pro Gly Arg 35 40 45
Val Pro Phe Ser Val Glu Phe Met Pro Pro Arg Asp Asp Ala Ala Glu 50 55 60
Glu Arg Leu Tyr Arg Ala Ala Glu Val Phe His Asp Leu Gly Ala Ser 65 70 75 80
Phe Val Ser Val Thr Tyr Gly Ala Gly Gly Ser Thr Arg Glu Arg Thr 85 90 95
Ser Arg lie Ala Arg Arg Leu Ala Lys Gin Pro Leu Thr Thr Leu Val 100 105 110 His Leu Thr Leu Val Asn His Thr Arg Glu Glu Met Lys Ala lie Leu 115 120 125
Arg Glu Tyr Leu Glu Leu Gly Leu Thr Asn Leu Leu Ala Leu Arg Gly 130 135 140
Asp Pro Pro Gly Asp Pro Leu Gly Asp Trp Val Ser Thr Asp Gly Gly 145 150 155 160
Leu Asn Tyr Ala Ser Glu Leu lie Asp Leu lie Lys Ser Thr Pro Glu 165 170 175
Phe Arg Glu Phe Asp Leu Gly lie Ala Ser Phe Pro Glu Gly His Phe 180 185 190 Arg Ala Lys Thr Leu Glu Glu Asp Thr Lys Tyr Thr Leu Ala Lys Leu 195 200 205
Arg Gly Gly Ala Glu Tyr Ser lie Thr Gin Met Phe Phe Asp Val Glu 210 215 220
Asp Tyr Leu Arg Leu Arg Asp Arg Leu Val Ala Ala Asp Pro lie His 225 230 235 240 Gly Ala Lys Pro He He Pro Gly He Met Pro He Thr Glu Leu Arg
245 250 255
Ser Val Arg Arg Gin Val Glu Leu Ser Gly Ala Gin Leu Pro Ser Gin 260 265 270
Leu Glu Glu Ser Leu Val Arg Ala Ala Asn Gly Asn Glu Glu Ala Asn 275 280 285
Lys Asp Glu He Arg Lys Val Gly He Glu Tyr Ser Thr Asn Met Ala 290 295 300
Glu Arg Leu' He Ala Glu Gly Ala Glu Asp Leu His Phe Met Thr Leu
305 310 315 320 Asn Phe Thr Arg Ala Thr Gin Glu Val Leu Tyr Asn Leu Gly Met Ala
325 330 335
Pro Ala Trp Gly Ala Glu His Gly Gin Asp Ala Val Arg 340 345
<210>, 3 . <211> 46 <212> DNA
<213> Artificial- sequence
<220>
<223> Description of the artificial sequence: Primer metF-EVP5
<400> 3 gatctaggat ccaaaggagg acaaccatgt ccctaacgaa catccc 46
<210> 4
<211> 32
<212> DNA
<213> Artificial sequence
<220>
<223> Description of the artificial sequence: Primer metF-EVP3 <400> 4 gatctactcg agttcttcta gttggctcgg ca 32

Claims

What is claimed is :
1. An isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence chosen from the group consisting of
a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,
c) polynucleotide which is complementary to the polynucleotides of a) or b) , and
d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c) .
2. A polynucleotide as claimed in claim 1, wherein the polynucleotide is a preferably recombinant DNA which is capable of replication in coryneform bacteria.
3. A polynucleotide as claimed in claim 1, wherein the polynucleotide is an RNA.
4. A polynucleotide as claimed in claim 2, comprising the nucleic acid sequence as shown in SEQ ID No. 1.
5. A DNA as claimed in claim 2 which is capable of replication, comprising
(i) the nucleotide sequence shown in SEQ ID No. 1, or (ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
(iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii) , and optionally
(iv) sense mutations of neutral function in (i) .
6. A polynucleotide sequence as claimed in claim 2, which codes for a polypeptide which comprises the amino acid sequence in SEQ ID No. 2.
7. A coryneform bacterium in which the metF gene is enhanced, in particular over-expressed.
8. A coryneform bacterium serving as the host cell, which contains a vector which carries a polynucleotide as claimed in claim 1.
9. A process for the fermentative preparation of L-amino acids, in particular L-methionine, which comprises carrying out the following steps:
a) fermentation of the coryneform bacteria which produce the desired L-amino acid and in which at least the metF gene or nucleotide sequences which code for it are enhanced, in particular over- expressed;
b) concentration of the L-amino acid in the medium or in the cells of the bacteria, and
c) isolation of the L-amino acid.
10. A process as claimed in claim 9, wherein bacteria in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
11. A process as claimed in claim 9, wherein bacteria in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
12. A process as claimed in claim 9, wherein a strain transformed with a plasmid vector is employed, and the plasmid vector carries the nucleotide sequence which codes for the metF gene. ' ~"
13. A process as claimed in claim 9, wherein the expression of the polynucleotide (s) which code(s) for the metF gene is enhanced, in particular over- expressed.
14. A process as claimed in claim 9, wherein the catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide metF codes are increased.
15. A process as claimed in claim 9, wherein for the preparation of L-amino acids, in particular L- methionine, coryneform microorganisms in which at the same time one or more of the genes chosen from the group consisting of
15.1 the lysC gene which codes for a feed back resistant aspartate kinase,
15.2 the gap gene which codes for glycerolaldehyde 3-phosphate dehydrogenase,
15.3 the pgk gene which codes for 3-phosphoglycerate kinase,
15.4 the pyc gene which codes for pyruvate carboxylase,
15.5 the tpi gene which codes for triose phosphate isomerase,
15.6 the metA gene which codes for homoserine 0- acetyltransferase,
15.7 the metB gene which codes for cystathionine gamma-synthase,
15.8 the aecD gene which codes for cystathionine gamma-lyase,
15.9 the glyA gene which codes for serine hydroxymethyltransferase,
15.10 the metY gene which codes for 0- acetylhomoserine sulfhydrylase,
is or are amplified or over-expressed are fermented.
16. A process as claimed in claim 9, wherein for the preparation of L-amino acids, in particular L- methionine, coryneform microorganisms in which at the same time one or more of the genes chosen from the group consisting of
16.1 the thrB gene which codes for homoserine kinase,
16.2 the ilvA gene which codes for threonine dehydratase,
16.3 the thrC gene which codes for threonine synthase,
16.4 the ddh gene which codes for meso- diaminopimelate D-dehydrogenase,
16.5 the pck gene which codes for phosphoenol pyruvate carboxykinase,
16.6 the pgi gene which codes for glucose 6- phosphate isomerase,
16.7 the poxB gene which codes for pyruvate oxidase,
is or are attenuated are fermented.
17. A process as claimed in one or more of claims 9-16, wherein microorganisms of the species Corynebacterium glutamicum are employed.
18. A process as claimed in claim 17, wherein the Corynebacterium glutamicum strain ATCC13032/pCREmetF is employed.
19. A process for the preparation of an L-methionine- containing animal feedstuffs additive from fermentation broths, which comprises the step's
a) culture and fermentation of an L-methionine- producing microorganism in a fermentation medium;
b) removal of water from the L-methionine-containing fermentation broth (concentration) ;
c) removal of an amount of 0 to 100 wt.% of the biomass formed during the fermentation; and
d) drying of the fermentation broth obtained according to b) and/or c) to obtain the animal feedstuffs additive in the desired powder or granule form.
20. A process as claimed in claim 19, wherein microorganisms in which further genes of the biosynthesis pathway of L-methionine are additionally enhanced are employed.
21. A process as claimed in claim 20, wherein microorganisms in which the metabolic pathways which reduce the formation of L-methionine are at least partly eliminated are employed.
22. A process as claimed in claim 20, wherein the expression of the polynucleotide (s) which code(s) for the metF gene is enhanced, in particular over- expressed.
23. A process as claimed in one or more of claims 19 to 22, wherein microorganisms of the species Corynebacterium glutamicum are employed.
24. A process as claimed in claim 23, wherein the Corynebacterium glutamicum strain ATCC13032/pCREmetF is employed.
25. A process as claimed in claimed claim 19, wherein one or more of the following steps is or are additionally carried out:
e) addition of one or more organic substances, including L-methionine and/or D-methionine and/or the racemic mixture D, L-methionine, to the_ products obtained according to b) , c) and/or d) ;
f) addition of auxiliary substances chosen from the group consisting of silicas, silicates, stearates, grits and bran to the substances obtained according to b) to e) for stabilization and to increase the storability; or
g) conversion of the substances obtained according to b) to f) into a form stable to the animal stomach, in particular rumen, by coating with film-forming agents.
26. A process as claimed in claim 19 or 25, wherein a portion of the biomass is removed.
27. A process as claimed in claim 26, wherein up to 100% of the biomass is removed.
28. A process as claimed in claim 19 or 25, wherein the water content is up to 5 wt.%.
29. A process as claimed in claim 28, wherein the water content is less than 2 wt.%.
30. A process as claimed in.claims 25, 26, 27, 28 or 29, wherein the film-forming agents are metal carbonates, silicas, silicates, alginates, stearates, starches, gums or cellulose ethers.
31. An animal feedstuffs additive prepared as claimed in claims 19 to 30.
32. An animal feedstuffs additive as claimed in claim 31, which comprises 1 wt.% to 80 wt.% L-methionine, D- methionine, D, L-methionine or a mixture thereof, based on the dry weight of the animal feedstuffs additive.
33. A process' for discovering RNA, cDNA and DNA in order to isolate nucleic acids, or polynucleotides or genes which code for methylene tetrahydrofolate reductase or have a high similarity with the sequence of the methylene tetrahydrofolate reductase gene, which comprises employing the polynucleotide sequences as claimed in claim 1, 2, 3 or 4 as hybridization probes.
EP01967192A 2000-08-02 2001-07-17 Nucleotide sequences which code for the metf gene Withdrawn EP1307477A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10053942 2000-08-02
DE10053942 2000-08-02
DE10109686 2001-02-28
DE10109686A DE10109686A1 (en) 2000-08-02 2001-02-28 New nucleotide sequences coding for the metf gene
PCT/EP2001/008224 WO2002010206A2 (en) 2000-08-02 2001-07-17 Nucleotide sequences which code for the metf gene

Publications (1)

Publication Number Publication Date
EP1307477A2 true EP1307477A2 (en) 2003-05-07

Family

ID=26007537

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01967192A Withdrawn EP1307477A2 (en) 2000-08-02 2001-07-17 Nucleotide sequences which code for the metf gene

Country Status (3)

Country Link
EP (1) EP1307477A2 (en)
AU (1) AU2001287631A1 (en)
WO (1) WO2002010206A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1247868A3 (en) * 2001-04-03 2002-10-30 Degussa AG Process for the production by fermentation of D-pantothenic acid and/or its salts
DE10239082A1 (en) * 2002-08-26 2004-03-04 Basf Ag Fermentative production of sulfur-containing fine chemicals, useful e.g. as feed additive, by culturing bacteria containing heterologous sequence for O-acetylhomoserine sulfhydrolase
DE10239073A1 (en) 2002-08-26 2004-03-11 Basf Ag Fermentative production of sulfur-containing fine chemicals, useful e.g. as feed additive, by culturing bacteria containing heterologous sequence for homoserine O-acetyltransferase
DE10239308A1 (en) * 2002-08-27 2004-03-11 Basf Ag Fermentative production of sulfur-containing fine chemicals, useful e.g. as feed additive, by culturing bacteria containing heterologous sequence for methionine synthase
KR100651220B1 (en) 2004-06-29 2006-11-29 씨제이 주식회사 L-methionine producing strain and L-methionine production method using the strain
AR083468A1 (en) 2010-10-25 2013-02-27 Metabolic Explorer Sa INCREASING NADPH'S AVAILABILITY FOR METIONIN PRODUCTION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009819A2 (en) * 1987-06-12 1988-12-15 Massachusetts Institute Of Technology C. glutamicum threonine biosynthetic pathway
GB2223754B (en) * 1988-09-12 1992-07-22 Degussa Dna encoding phosphoenolpyruvate carboxylase
DE3908201A1 (en) * 1989-03-14 1990-09-27 Degussa METHOD FOR THE FERMENTATIVE MANUFACTURE OF L-LYSINE
KR920008381B1 (en) * 1990-12-31 1992-09-26 제일제당 주식회사 Lysine production method by recombinant Corynebacterium glutamicum
JPH07503855A (en) * 1992-02-20 1995-04-27 ジェネンコア インターナショナル インコーポレーテッド Methionine biosynthesis using a sulfur reducing source
MXPA01013123A (en) * 1999-06-25 2002-06-21 Basf Ag Corynebacterium glutamicum.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0210206A2 *

Also Published As

Publication number Publication date
WO2002010206A2 (en) 2002-02-07
WO2002010206A3 (en) 2002-05-02
AU2001287631A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
EP1390504B1 (en) Nucleotide sequences which code for the metd gene
WO2002010209A1 (en) Nucleotide sequences which code for the meth gene
WO2002020542A2 (en) Nucleotide sequences which code for the gap2 gene
EP2085482B1 (en) Nucleotide sequences which code for the metY gene
EP1320593B1 (en) Process for the preparation of L-lysine using CYSD, CYSN, CYSK, CYSE AND/or CYSH OF C. GLUTAMICUM
US6942996B2 (en) Isolated polynucleotide from Corynebacterium encoding a homocysteine methyltransferase
US20020049305A1 (en) Nucleotide sequences which code for the metF gene
US6822085B2 (en) Nucleotide sequences which code for the cysD, cysN, cysK, cysE and cysH genes
US6812016B2 (en) Nucleotide sequences which code for the metY gene
US6759224B2 (en) Nucleotide sequences which code for the sahH gene
US6958228B2 (en) Nucleotide sequence which code for the metH gene
US6815196B2 (en) Nucleotide sequences encoding o-succinylhomoserine sulfhydrylase
WO2002010206A2 (en) Nucleotide sequences which code for the metf gene
WO2002010208A1 (en) Nucleotide sequences which code for the mete gene
WO2002027000A1 (en) Nucleotide sequences which code for the dep67 protein
EP1315820B1 (en) Nucleotide sequences which code for s-adenosyl homocysteinase (sahh)
AU7166500A (en) New nucleotide sequences which code for the pfk gene
EP1507008A2 (en) Nucleotide sequences which code for the sahH gene
EP1313757A2 (en) Nucleotide sequences which code for the metr and metz genes
WO2002018597A1 (en) Nucleotide sequences which code for the csta gene from corynebacterium glutamicum
EP1320616A2 (en) Sequences which code for the sige gene of corynebacterium glutamicum

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030103

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THIERBACH, GEORG

Inventor name: GREISSINGER, DIETER

Inventor name: BINDER, MICHAEL

Inventor name: HUTHMACHER, KLAUS

Inventor name: PFEFFERLE, WALTER

Inventor name: MOECKEL, BETTINA

Inventor name: BATHE, BRIGITTE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THIERBACH, GEORG

Inventor name: GREISSINGER, DIETER

Inventor name: BINDER, MICHAEL

Inventor name: HUTHMACHER, KLAUS

Inventor name: PFEFFERLE, WALTER

Inventor name: MOECKEL, BETTINA

Inventor name: BATHE, BRIGITTE

17Q First examination report despatched

Effective date: 20050224

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060818